The financing provides near-term liquidity but at significant dilution; watch for activation of later CDMO work packages and customer payments to assess whether the company can achieve self-sustaining revenue before needing further capital.
Price Chart
Executive Summary
Scinai Immunotherapeutics closed a $4.0 million private placement and warrant inducement transaction, issuing 2,458,334 ADSs (or pre-funded warrants) and Series A-1 warrants for up to 3,687,501 ADSs, plus exercised existing warrants for 879,194 ADSs at $1.20 per ADS. The proceeds extend the cash runway to late 2027, but the dilutive financing signals ongoing capital needs for a pre-revenue biotech with no reported revenue or earnings.
Key Facts
- Closed private placement of 2,458,334 ADSs (or pre-funded warrants) and Series A-1 warrants for up to 3,687,501 ADSs.
- Closed immediate exercise of existing warrants for 879,194 ADSs at a reduced exercise price of $1.20 per ADS, with issuance of new Series A-1 warrants for up to 1,318,791 ADSs.
- Aggregate gross proceeds of approximately $4.0 million before fees and expenses.
- Proceeds to be used for CDMO customer programs, additional CDMO contracts, and selective immunotherapy pipeline investment.
- Company estimates operating runway to late 2027 based on current plan and budget; activation of later CDMO phases could extend to 2028.
- A.G.P./Alliance Global Partners acted as sole placement agent.
Financial Impact
$4.0 million gross proceeds from dilutive financing, with potential future dilution from up to 5,006,292 additional ADSs issuable upon exercise of Series A-1 warrants.
Risk Factors
- Substantial dilution from the private placement and warrant exercise, with additional overhang from up to 5 million ADSs issuable upon exercise of Series A-1 warrants.
- Cash runway depends on achieving sales assumptions, timely customer payments, and successful execution; customer termination rights and geopolitical risks in Israel add uncertainty.
- No reported revenue or earnings; pre-revenue biotech with high cash burn rate and need for additional financing.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-110069 |
| Document: ea0308852-6k_scinai.htm | 0001213900-26-110069 |
| Document: 0001213900-26-110069-index-headers.html | 0001213900-26-110069 |
| Document: 0001213900-26-110069-index.html | 0001213900-26-110069 |
| Document: 0001213900-26-110069.txt | 0001213900-26-110069 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 6-K | $0.6813 | awaiting T+60 | — | $0.5310 (−22.06%) |
Oct 16, 2026 11d ago | 6-K | $0.7520 | awaiting T+60 | — | $0.5310 (+29.39%) |
Oct 16, 2026 11d ago | Press Release | $0.7524 | awaiting T+60 | — | $0.5310 (+29.43%) |
Oct 15, 2026 12d ago | 6-K | $0.9015 | awaiting T+60 | — | $0.5310 (+41.10%) |
Oct 13, 2026 14d ago | 6-K | $1.23 | awaiting T+60 | — | $0.5310 (−56.83%) |
Oct 6, 2026 21d ago | EFFECT | $1.22 | awaiting T+60 | — | $0.5310 (+56.48%) |
Sep 21, 2026 5w ago | 6-K | $1.69 | awaiting T+60 | — | $0.5310 (−68.58%) |
Aug 26, 2026 8w ago | 6-K | $2.87 | awaiting T+60 | — | $0.5310 (+81.50%) |
Aug 19, 2026 9w ago | 6-K | $0.2740 | awaiting T+60 | — | $0.5310 (−93.80%) |
Jun 17, 2026 18w ago | 6-K | $0.3370 $0.2440 | ▼ −27.60% | ▼ −30.28% | $0.5310 (+57.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers